First‐Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta‐Analysis
BackgroundThere is no consensus on the most effective and best tolerated first‐line antiarrhythmic treatment for fetal tachyarrhythmia. The purpose of this systematic review and meta‐analysis was to compare the efficacy, safety, and fetal–maternal tolerance of first‐line monotherapies for fetal supr...
Main Authors: | Tarek Alsaied, Shankar Baskar, Munes Fares, Fares Alahdab, Richard J Czosek, Mohammad Hassan Murad, Larry J Prokop, Allison A Divanovic |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-12-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.117.007164 |
Similar Items
-
New Russian antiarrhythmic agent nibentan: clinical effectiveness and pharmacokinetics in supraventricular arrhythmia management
by: A. E. Radzevich, et al.
Published: (2007-10-01) -
SGLT2 Inhibitors and Their Antiarrhythmic Properties
by: Ewald Kolesnik, et al.
Published: (2022-01-01) -
Fetal Tachyarrhythmia Management from Digoxin to Amiodarone—A Review
by: Liliana Gozar, et al.
Published: (2022-02-01) -
Treatment of fetus with tachyarrhythmia
by: Daniela Katić, et al.
Published: (2023-01-01) -
Impact of transesophageal electrophysiological study on midterm management of pediatric tachyarrhythmias
by: Anand Manickavasagam, et al.
Published: (2022-01-01)